Search FLGT
Fulgent Genetics, Inc.
Nasdaq · CIK 1674930
Last close21.48
Daily change+0.18 (0.85%)
10 Years gain+106.74%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
FLGT · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
30.0Momentum
24.2Acceleration
24.2Confidence
84.0Annual Revenue12
Quarterly Revenue52
Annual CFO12
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.7 / 25
Quality4.7 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators4.6 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 9.169%.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 5.168 percentage points.
Key Metrics
Revenue Growth TTM14.85%OK
Revenue CAGR 3Y-19.52%OK
Gross Margin36.33%OK
Operating Margin-32.8%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-9.26%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-9.17%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $322.67M | $130.88M | -$91.10M | -$101.64M | -$124.21M | 40.56% | -28.23% | -38.49% | -8.72% | 30.78M |
| 2025 FY Dec 31, 2024 | $283.47M | $107.22M | -$73.92M | $21.06M | -$19.26M | 37.82% | -26.08% | -6.79% | -6.1% | 30.24M |
| 2025 FY Dec 31, 2023 | $289.21M | $104.46M | -$195.53M | $27.00M | $4.80M | 36.12% | -67.61% | 1.66% | -13.88% | 29.78M |
| 2024 FY Dec 31, 2022 | $618.97M | $366.90M | $178.53M | $253.52M | $234.75M | 59.28% | 28.84% | 37.93% | 12.63% | 30.96M |
| 2023 FY Dec 31, 2021 | $992.58M | $777.05M | $675.95M | $538.58M | $514.77M | 78.29% | 68.1% | 51.86% | 79.36% | 30.98M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $322.40M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-326136, 0001193125-25-271013 |
| Revenue Growth TTM | 14.85% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-326136, 0001193125-25-271013 |
| Revenue CAGR 3Y | -19.52% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-079169 |
| Revenue CAGR 5Y | -5.21% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-079169 |
| Gross Profit CAGR 3Y | -29.08% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-079169 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-326136, 0001193125-25-271013 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 36.33% | Gross Profit / Revenue | OK | 0001193125-26-326136, 0001193125-25-271013 |
| Operating Margin | -32.8% | Operating Income / Revenue | OK | 0001193125-26-326136, 0001193125-25-271013 |
| ROIC | -9.26% | NOPAT / Average Invested Capital | OK | 0001193125-26-326136, 0001193125-25-271013 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-326136 |
| Current Ratio | 6.34x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $11.51 | Revenue / Diluted Shares | OK | 0001193125-26-326136, 0001193125-25-271013 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |